While CPAP can have transformative effects for some patients with obstructive sleep apnea (OSA), many patients are unable to tolerate PAP therapy long-term and due to limited alternatives remain untreated. Based on recent publications and conference sessions, there is a clear need for novel, personalized treatment options Through state-of-the-art reviews and an in-depth panel discussion, we will provide the audience with current best practices for more established therapies (e.g. oral appliances, hypoglossal nerve stimulation) and speak to critical issues including regulatory considerations for the development of novel, personalized alternative therapies (e.g. ansa cervicale stimulation, endotype-targeted drug therapy, DREADD).
• Understand better current and future approaches to optimal patient selection for available OSA therapies
• Describe recent progress and challenges in the (pre)clinical development of new drug/device therapies
• Describe regulatory requirements to translate interventions into FDA-approved clinical therapies
Kathy Page, AD
Bradley Edwards, PhD
David Kent, MD
Christopher Schmickl, MD, PhD
Bharati Prasad, MD, ATSF
Lydia Kim, MD
Nargues Weir, MD
Susan Redline, MD, MPH
Patient Speaker
What's New with Weight Loss, Oral Appliances, and Upper Airway Surgery?
Electrical Stimulation: Hypoglossal Nerve Stimulation, Ansa Cervicale Stimulation, and Transoral Daytime Neurostimulation - Presentation withheld at the speaker's request
Clinical Drug Discovery Based on Endotypes
Preclinical Drug Discovery: Cannabimimetics, Intranasal Leptin, DREADD, and Beyond
FDA Perspective: Regulatory Considerations for the Development of New OSA Therapies 1
FDA Perspective: Regulatory Considerations for the Development of New OSA Therapies 2
Panel Discussion Plus Q&A